Generation Bio Co.
Generation Bio Co. (GBIO): 1 pipeline candidate · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.1 months
D/E 1.41 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for Generation Bio Co.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$24.1M
Quarterly Burn
$52.7M
Runway
5.1 mo
Revenue
$1.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| hemophilia a program | Preclinical |
Frequently asked questions
How many drug candidates are in Generation Bio Co.'s pipeline?
Generation Bio Co. (GBIO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Generation Bio Co.'s lead drug candidate?
Generation Bio Co.'s most advanced tracked candidate is hemophilia a program (Preclinical) for Hemophilia A.
What is Generation Bio Co.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Generation Bio Co. has approximately 5.1 months of cash runway.
Who is the CEO of Generation Bio Co.?
Geoff Mc is the chief executive officer of Generation Bio Co. (GBIO).
Get the full picture on Generation Bio Co.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.